We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.
- Authors
Sood, Ajit; Ahuja, Vineet; Midha, Vandana; Sinha, Saroj Kant; Ganesh Pai, C.; Kedia, Saurabh; Mehta, Varun; Bopanna, Sawan; Abraham, Philip; Banerjee, Rupa; Bhatia, Shobna; Chakravartty, Karmabir; Dadhich, Sunil; Desai, Devendra; Dwivedi, Manisha; Goswami, Bhabhadev; Kaur, Kirandeep; Khosla, Rajeev; Kumar, Ajay; Mahajan, Ramit
- Abstract
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD. (Intest Res 2020;18:355- 378)
- Subjects
INFLAMMATORY bowel diseases; SALICYLIC acid; ULCERATIVE colitis
- Publication
Intestinal Research, 2020, Vol 18, Issue 4, p355
- ISSN
1598-9100
- Publication type
Article
- DOI
10.5217/ir.2019.09176